Glencore looks to sell stake in Tampakan copper mine

Glencore Xstrata has informed Indophil, its partner in the Tampakan greenfield copper project in the Philippines, of its preference to divest its majority stake in the project.

Glencore Xstrata has informed Indophil, its partner in the Tampakan greenfield copper project in the Philippines, of its preference to divest its majority stake in the project.

Glencore inherited the Tampakan stake as part of its takeover of Xstrata, but agreed to offer the project up for a possible sale by auction as one of the conditions imposed by China’s Ministry of Commerce in its approval of the Xstrata deal.

Under Mofcom’s terms, if Glencore fails to agree a deal for the sale of the Las Bambas copper project in Peru, it must nominate a trustee to sell one of four copper projects – Tampakan, Frieda River, El Pachon or Alumbrera – by auction with no minimum reseve price

In November, Glencore announced plans to sell its 80% stake in Frieda River to PanAust, subject to Mofcom approval, in a deal that suggested it was confident it would find an attractive bid for Las Bambas.

“Glencore Xstrata has informed Indophil of its preference to divest its stake in Tampakan,” Indophil told investors on Thursday January 30.

“This is consistent with Glencore’s preference to not develop greenfield projects, and its publicly announced plan to sell its interests in the Las Bambas copper project in Peru and … Frieda River,” it said.

China Minmetals’ majority-owned subsidiary MMG has been considered the front-runner to buy Las Bambas, but the multibillion-dollar project has also attracted interest from a consortium comprising Teck, Newmont Mining, Blackstone and Magris Resources, according to media reports.

The move to divest Frieda River and Tampakan suggests the sale of Las Bambas is entering its final stages. Under the Mofcom agreement, a sale must be announced before September 30.

Investec estimates the ungeared value of the Las Bambas mine at $6.2 billion, the asset management group said on Thursday that Glencore may struggle to find a buyer willing to pay that price for the asset.

“If an acquirer were to spend $6 billion for the asset, it would need access to close to US$10bn to get Las Bambas into production, not a small figure by any measure,” Investec said.

“We believe that there are very few companies globally with the resources to afford this, particularly when major miners are typically focussing on capex reductions and reducing leverage,” the analysts said.

Investec assumes a sale price of $4.5 billion in its valuation of Glencore, which it has a sell rating on.

Glencore declined to comment on the status of the Las Bambas sale.

Mark Burton
mburton@metalbulletin.com
Twitter: @mburtonmb

What to read next
The influential annual treatment and refining charge (TC/RC) benchmark that sets the price that smelters charge miners to process their copper concentrate could be at risk, according to multiple market sources, although most believe the system, or elements of it, will remain
Fastmarkets' initial low-carbon premium for nickel briquettes captured existing regional price differences, with growing awareness and legislative incentives indicating there is potential for a strong market to emerge
The Chilean government is pushing ahead with plans for a new copper smelter despite the global smelting crisis, Chile’s minister of mining, Aurora Williams told Fastmarkets, adding that the state will also play a key role in developing the country’s premium lithium assets
Just under two weeks ago, the chair of BHP made a phone call to his counterpart at mining peer Anglo American and set in motion a flurry of activity designed to create the largest copper producer in the world
Brazilian aluminium supply coming from Companhia Brasileira de Alumínio (CBA) is said to have tightened, helping to boost the P1020A ingot premium, market participants told Fastmarkets in the two weeks to Wednesday April 24
In anticipation of a tight market, copper concentrate traders have locked in 2025 volumes at notably low treatment charges, with deals being placed well below the long-term industry benchmarks